297 related articles for article (PubMed ID: 29375575)
21. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
22. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling.
Nair S; Wang JB; Tsao ST; Liu Y; Zhu W; Slayton WB; Moreb JS; Dong L; Chang LJ
Curr Gene Ther; 2019; 19(1):40-53. PubMed ID: 30444200
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.
Gowda A; Ramanunni A; Cheney C; Rozewski D; Kindsvogel W; Lehman A; Jarjoura D; Caligiuri M; Byrd JC; Muthusamy N
MAbs; 2010; 2(1):35-41. PubMed ID: 20081380
[TBL] [Abstract][Full Text] [Related]
24. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome.
Xia L; Wang Y; Li T; Hu X; Chen Q; Liu L; Jiang B; Li C; Wang H; Wang S; Yang G; Bao Y
Cancer Med; 2019 Jun; 8(6):2930-2941. PubMed ID: 31050207
[TBL] [Abstract][Full Text] [Related]
25. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
[TBL] [Abstract][Full Text] [Related]
26. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
[TBL] [Abstract][Full Text] [Related]
27. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
28. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
29. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
30. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
[TBL] [Abstract][Full Text] [Related]
31. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract][Full Text] [Related]
33. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
[TBL] [Abstract][Full Text] [Related]
34. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
35. Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder.
Alvarez-Mon MA; Gómez-Lahoz AM; Orozco A; Lahera G; Diaz D; Ortega MA; Albillos A; Quintero J; Aubá E; Monserrat J; Alvarez-Mon M
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33808804
[TBL] [Abstract][Full Text] [Related]
36. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
[TBL] [Abstract][Full Text] [Related]
37. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
Golay J; D'Amico A; Borleri G; Bonzi M; Valgardsdottir R; Alzani R; Cribioli S; Albanese C; Pesenti E; Finazzi MC; Quaresmini G; Nagorsen D; Introna M; Rambaldi A
J Immunol; 2014 Nov; 193(9):4739-47. PubMed ID: 25267972
[TBL] [Abstract][Full Text] [Related]
38. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
39. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.
Xue Q; Bettini E; Paczkowski P; Ng C; Kaiser A; McConnell T; Kodrasi O; Quigley MF; Heath J; Fan R; Mackay S; Dudley ME; Kassim SH; Zhou J
J Immunother Cancer; 2017 Nov; 5(1):85. PubMed ID: 29157295
[TBL] [Abstract][Full Text] [Related]
40. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]